Fetuin-Mineral Complex Reflects Extraosseous Calcification Stress in CKD
Authors:
- Takayuki HamanoTHTakayuki Hamano
- Isao MatsuiIMIsao Matsui
- Satoshi MikamiSMSatoshi Mikami
- Kodo TomidaKTKodo Tomida
- Naohiko FujiiNFNaohiko Fujii
- Enyu ImaiEIEnyu Imai
- Hiromi RakugiHRHiromi Rakugi
- Yoshitaka IsakaYIYoshitaka Isaka
- 1 November 2010
- journal article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 21 (11) , 1998-2007
Abstract
Fetuin-A is an important inhibitor of extraosseous calcification, but some of the studies that used ELISAs did not identify a significant relationship between serum fetuin-A levels and vascular calcification in patients with chronic kidney disease (CKD). Here, we used centrifugation to separate a fetuin-mineral complex (FMC) composed of fetuin-A, fibrinogen, fibronectin-1, and calcium from the serum of hemodialysis patients. In addition, we analyzed serum fetuin-A levels of 73 patients with diabetes and CKD (predialysis) after centrifugation. Fetuin-A concentrations were significantly lower in supernatants than in serum from patients at any stage of CKD, indicating systemic circulation of FMC in these patients. With greater severity of CKD, the contribution of FMC to total fetuin-A increased. Despite the absence of a correlation between serum fetuin-A and coronary artery calcification scores (CACS), supernatant fetuin-A negatively correlated with CACS and the extent to which centrifugation reduced fetuin-A (reduction ratio [RR]) positively correlated with CACS. In a longitudinal study of 12 hemodialysis patients with secondary hyperparathyroidism, parathyroidectomy and cinacalcet therapy each significantly reduced the RR without changing supernatant fetuin-A levels after 1 month, suggesting a reduction in FMC. Moreover, the magnitude of cinacalcet-induced reduction in parathyroid hormone correlated with the decrease in RR but not with changes in serum or supernatant fetuin-A. These data suggest that a quantitative measure of FMC, not supernatant or serum fetuin-A as measured in previous studies, reflects extraosseous calcification stress.Keywords
This publication has 48 references indexed in Scilit:
- Fetuin-A Protects against Atherosclerotic Calcification in CKDJournal of the American Society of Nephrology, 2009
- Relation of Serum Fetuin-A Levels to Coronary Artery Calcium in African-American Patients on Chronic HemodialysisThe American Journal of Cardiology, 2009
- The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not Matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysisNephrology Dialysis Transplantation, 2008
- Association of serum fetuin-A levels with mortality in dialysis patientsKidney International, 2007
- Association of Fetuin-A With Mitral Annular Calcification and Aortic Stenosis Among Persons With Coronary Heart DiseaseCirculation, 2007
- Association of serum fetuin‐A with carotid arterial stiffnessClinical Endocrinology, 2006
- Serum Albumin, C-Reactive Protein, Interleukin 6, and Fetuin A as Predictors of Malnutrition, Cardiovascular Disease, and Mortality in Patients With ESRDAmerican Journal of Kidney Diseases, 2006
- Changes in Cardiovascular Calcification After Parathyroidectomy in Patients With ESRDAmerican Journal of Kidney Diseases, 2005
- Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patientsNephrology Dialysis Transplantation, 2005
- Natural history of vascular calcification in dialysis and transplant patientsNephrology Dialysis Transplantation, 2004